ABT vs FOSL · P/E 25, rev $44.33B vs rev $434.4M
Abbott Laboratories (ABT) versus Fossil Group Inc (FOSL) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Fossil Group Inc (FOSL) is a footwear & accessories company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported FOSL revenue for 2026-07-04 was $434.4M. Net income was -$11.3M. Revenue was up 93.3% from 2026-04-04 to 2026-07-04. FOSL currently screens at market cap $248.2M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. FOSL currently screens at market cap $248.2M.
Not investment advice. Open the ABT and FOSL stock pages for the full models.
Not investment advice.